1.665 0 (0%) | 02-05 15:00 | |||||||||||||
|
|
Short term | ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 2.21 | 1-year : | 2.59 |
Resists | First : | 1.89 | Second : | 2.21 |
Pivot price | 1.63 ![]() |
|||
Supports | First : | 1.59 | Second : | 1.39 |
MAs | MA(5) : | 1.63 ![]() |
MA(20) : | 1.66 ![]() |
MA(100) : | 1.74 ![]() |
MA(250) : | 5.4 ![]() |
|
MACD | MACD : | -0.1 ![]() |
Signal : | -0.1 ![]() |
%K %D | K(14,3) : | 51.9 ![]() |
D(3) : | 47 ![]() |
RSI | RSI(14): 49.4 | |||
52-week | High : | 9.6 | Low : | 1.37 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ TLIS ] has closed below upper band by 43.1%. Bollinger Bands are 31.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 1.67 - 1.67 | 1.67 - 1.68 |
Low: | 1.65 - 1.66 | 1.66 - 1.66 |
Close: | 1.65 - 1.67 | 1.67 - 1.68 |
Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also offers Talis One COVID-19 Test System, which focuses on detection of SARS-CoV-2, the virus that causes COVID-19. In addition, it develops Talis One assay kit for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A, influenza B, and respiratory syncytial virus. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Menlo Park, California.
Thu, 10 Oct 2024
Baker Bros. Advisors LP's Strategic Acquisition in Talis Biomedical Corp - Yahoo Finance
Mon, 09 Sep 2024
Talis Biomedical executive buys $44,240 in company stock - Investing.com
Tue, 03 Sep 2024
Talis Biomedical agrees to $32.5 million settlement - Investing.com
Mon, 26 Aug 2024
Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket - Benzinga
Mon, 07 Aug 2023
Chemical spill prompts hazmat response, evacuation at Redwood Shores biomedical firm - CBS San Francisco
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Medical - Devices
|
|
Shares Out | 0 (M) |
Shares Float | 2 (M) |
Held by Insiders | 765110 (%) |
Held by Institutions | 8.3 (%) |
Shares Short | 14 (K) |
Shares Short P.Month | 0 (K) |
EPS | -4.558e+007 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 0 % |
Operating Margin | -11 % |
Return on Assets (ttm) | 360.2 % |
Return on Equity (ttm) | -29.6 % |
Qtrly Rev. Growth | 408000 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | -45.18 |
EBITDA (p.s.) | -1.28782e+007 |
Qtrly Earnings Growth | -28.1 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | -40 (M) |
PE Ratio | -0.01 |
PEG Ratio | 0 |
Price to Book value | 0 |
Price to Sales | -0.04 |
Price to Cash Flow | 0.09 |
Dividend | 0 |
Forward Dividend | 17960 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |